HHS Announces Requested Updates to Testosterone Therapy Product Labels
Clinical Scorecard: HHS Proposes Revisions to Labeling for Testosterone Replacement Therapy Products
At a Glance
| Category | Detail |
|---|
| Condition | Testosterone Replacement Therapy |
| Key Mechanisms | Updates to safety and effectiveness information based on new clinical data. |
| Target Population | Men with hypogonadism and related conditions. |
| Care Setting | Men's healthcare and endocrinology. |
Key Highlights
- Removal of limitation of use for age-related hypogonadism.
- Updated information regarding prostate cancer risk.
- Revised warnings for benign prostatic hyperplasia.
- No significant increase in cardiovascular risks found in recent studies.
- Continued monitoring recommended for patients with severe symptoms.
Guideline-Based Recommendations
Diagnosis
- Assess risk and screen patients before treatment.
Management
- Testosterone replacement therapy contraindicated in men with metastatic prostate cancer.
Monitoring & Follow-up
- Monitor patients during therapy, especially those with severe benign prostatic hyperplasia.
Risks
- Important uncertainties remain regarding long-term effects of testosterone therapy.
Patient & Prescribing Data
Men with signs and symptoms of hypogonadism.
Updated labeling reflects current evidence on safety and effectiveness.
Clinical Best Practices
- Ensure prescribing information reflects the best available scientific evidence.
- Support informed treatment decisions based on updated clinical data.
Related Resources & Content
